Tsumura & Co.

4540.T
Drug Manufacturers - Specialty & Generic
2026/08/21 Updated
Market Cap: $1.8B (¥279.4B)
Stock Price: $23.57 (¥3,748)
Exchange Rate: 1 USD = ¥158.98

Q1 FY2027 Earnings Report for the Period Ended March 2027 (Japanese GAAP)

Consolidated results for the first quarter of FY2027. Revenue is expected to increase year over year; disclosure of trends in domestic and international segment revenue. Key indicators by segment revenue, cost of sales, SG&A, operating income, ordinary income, and quarterly net income attributable to owners of parent are disclosed.

Importance:
Page Updated: August 6, 2026
IR Disclosure Date: August 6, 2026

Key Figures

  • Sales: Unknown (no data in PDF)
  • Operating income: Unknown
  • Ordinary income: Unknown
  • Total net assets: Unknown

AI要約

Section Heading

This quarter’s results summary includes explanations of management performance, financial position, notes on the preparation of consolidated financial statements, and the trends in quarterly net income and segment information. Specific figures such as revenue and various expense items are available in the relevant tables of the PDF; this summary notes them as Unknown. Segment revenue and contributions from drug development cases, and the breakdown of Growing prescriptions are provided as notes.

Section 2 Heading

There is also coverage of cash flow related to the earnings, financial position, and outlook. The quarterly financial statements and notes include changes in cash and cash equivalents, breakdown of assets and liabilities, and components of net assets, with YoY comparisons. Future outlook details are limited within this document.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Tsumura & Co.

Company overview · Stock price · Financial data · All IR

View company page →